Last updated: August 15, 2026
The fixed-dose combination of olmesartan medoxomil, amlodipine besylate and hydrochlorothiazide is marketed in the United States as Tribenzor. It is a small-molecule antihypertensive approved by the FDA in 2010 for adults whose blood pressure is not adequately controlled with dual therapy or who are already receiving the three components separately. The product has limited current growth potential because all three active ingredients are generic, combination-product patent protection has largely expired or is near expiry, and physicians can substitute lower-cost component regimens.
Tribenzor’s commercial value has shifted from branded growth to residual demand, prescription convenience and generic substitution. Daiichi Sankyo does not publicly report standalone Tribenzor revenue, so the product’s financial trajectory must be assessed through prescription trends, generic availability, reimbursement pressure and the broader decline of the Benicar franchise.
What is olmesartan medoxomil, amlodipine and hydrochlorothiazide?
Olmesartan medoxomil, amlodipine and hydrochlorothiazide combine three antihypertensive mechanisms:
| Component |
Drug class |
Primary action |
| Olmesartan medoxomil |
Angiotensin II receptor blocker |
Blocks AT1 receptors and reduces vasoconstriction |
| Amlodipine besylate |
Calcium-channel blocker |
Relaxes arterial smooth muscle |
| Hydrochlorothiazide |
Thiazide diuretic |
Increases sodium and water excretion |
Tribenzor is available in three strengths:
| Olmesartan medoxomil |
Amlodipine |
Hydrochlorothiazide |
| 20 mg |
5 mg |
12.5 mg |
| 40 mg |
5 mg |
12.5 mg |
| 40 mg |
10 mg |
25 mg |
The product is administered once daily. Its principal commercial advantage is reduced pill burden. Its clinical disadvantage is that each dose component is fixed, limiting titration flexibility compared with prescribing the ingredients separately.
What is the FDA status of Tribenzor?
The FDA approved Tribenzor under NDA 022582 in July 2010. The approval covered treatment of hypertension in patients who require all three components to achieve blood-pressure control. The product is not approved for initial hypertension treatment in patients who have not previously received the individual components or an appropriate dual combination.[1]
The FDA labeling identifies standard risks associated with the ingredients:
- fetal toxicity associated with renin-angiotensin system blockade;
- hypotension and renal impairment;
- hyperkalemia from olmesartan;
- edema and cardiovascular effects from amlodipine;
- electrolyte abnormalities, glucose effects and photosensitivity from hydrochlorothiazide.
The FDA’s Drugs@FDA database should be used to confirm current marketing status, labeling history and any discontinued-status designation. The product’s regulatory value is substantially lower than at launch because the active ingredients and major dosage combinations are available separately as generic medicines.[1]
When did Tribenzor lose exclusivity?
Tribenzor’s exclusivity profile has two parts: exclusivity for the active pharmaceutical ingredients and protection for the fixed-dose combination.
Ingredient-level exclusivity
The core ingredients lost meaningful brand exclusivity at different times:
- olmesartan medoxomil was developed and commercialized earlier as Benicar;
- amlodipine became generic after Norvasc exclusivity ended;
- hydrochlorothiazide has been generic for decades.
The principal commercial protection for Tribenzor therefore depended on the fixed-dose combination, regulatory exclusivity and any listed formulation or method-of-use patents.
Fixed-dose combination protection
The key patent associated with the Tribenzor combination has been identified in patent and Orange Book records as U.S. Patent No. 7,691,001. The patent covers pharmaceutical compositions containing olmesartan medoxomil, amlodipine and hydrochlorothiazide. Its nominal term was subject to statutory adjustments and any applicable pediatric extension.[2][3]
The commercial result is clear: by the mid-2020s, Tribenzor no longer has a durable branded exclusivity position capable of supporting premium pricing. Any residual patent dispute would be narrow, product-specific and unlikely to restore broad market exclusivity.
What patents protect olmesartan, amlodipine and hydrochlorothiazide combinations?
The relevant intellectual-property estate includes several layers:
| Protection layer |
Commercial relevance |
| Olmesartan compound patents |
Historically protected Benicar and related products, but no longer provides a meaningful barrier to generic component supply |
| Fixed-dose combination patents |
Covered the combination of olmesartan, amlodipine and hydrochlorothiazide |
| Formulation patents |
May cover tablet composition, excipients, stability or manufacturing characteristics |
| Method-of-use patents |
Could cover treatment of hypertension or dosing in defined patient groups, although these claims are difficult to enforce broadly |
| Regulatory exclusivity |
Limited-duration protection attached to the original FDA approval |
U.S. Patent No. 7,691,001 is the most commercially significant identified combination patent. Patent scope and enforceability depend on the asserted claims, prosecution history, terminal disclaimers, patent-term adjustment and the specific generic product involved. An Orange Book listing does not establish validity or infringement.[2][3]
The combination has a weaker patent position than newer branded cardiovascular products because:
- all three active ingredients are established molecules;
- generic manufacturers can offer the components separately;
- clinical substitution does not require a new therapeutic mechanism;
- fixed-dose tablet claims are generally easier to design around than composition-of-matter claims.
Were there Paragraph IV challenges to Tribenzor?
Generic applicants may challenge listed patents through an Abbreviated New Drug Application and a Paragraph IV certification. A Paragraph IV certification asserts that a listed patent is invalid, unenforceable or not infringed.
Public patent records identify litigation involving Daiichi Sankyo and generic manufacturers concerning Tribenzor-related patent rights, including U.S. Patent No. 7,691,001. The commercial effect of those disputes was to delay or structure generic entry rather than preserve a long-term branded market.
A Paragraph IV case can create a 30-month stay of FDA approval under the Hatch-Waxman Act when the patent owner files suit within the statutory period. The stay does not itself establish patent validity. Generic entry can occur earlier through settlement, a court decision, patent expiration or a license.
The key business implication is that Tribenzor’s patent litigation was an entry-timing issue. It was not a sustainable defense against eventual generic erosion.
What is the Orange Book status of Tribenzor?
The Orange Book identifies FDA-approved drug products and relevant patents submitted by the sponsor. For Tribenzor, the Orange Book analysis should focus on:
- NDA 022582;
- listed dosage strengths;
- patents associated with the fixed-dose combination;
- pediatric exclusivity, if applicable;
- approved generic products and their therapeutic-equivalence codes.
Orange Book listings can change as patents expire, are delisted, or become irrelevant to later-approved products. Patent expiration should therefore be determined from the current Orange Book record and USPTO term data rather than from the original patent filing date alone.[2][3]
As a practical matter, the Orange Book no longer supports a high-value branded exclusivity thesis for Tribenzor. The relevant question is whether any remaining listed claim can delay a particular generic product, not whether the branded product retains a protected market.
How strong is the Tribenzor patent estate?
The patent estate is commercially weak to moderate, depending on the date and the specific generic challenge.
Strengths
- The fixed-dose combination addressed a defined pharmaceutical composition.
- A combination patent can delay entry even after individual ingredients become generic.
- The product offered a differentiated once-daily tablet during the protected period.
Weaknesses
- The composition-of-matter patents for the individual ingredients are no longer a meaningful barrier.
- Physicians can reproduce the treatment using separate generic tablets.
- Combination-product claims are vulnerable to invalidity and non-infringement arguments.
- Generic manufacturers can compete through multiple strengths and separate-component substitution.
- The product has limited technological differentiation.
The estate does not resemble the patent position of a biologic, long-acting injectable or complex drug-delivery system. There is no biosimilar-style manufacturing barrier. Manufacturing requires conventional small-molecule tablet production, analytical controls and compliance with FDA current good manufacturing practices.
What generic entry risks exist for Tribenzor?
Generic entry risk is high. The main substitution paths are:
- a therapeutically equivalent generic three-drug tablet;
- separate generic olmesartan, amlodipine and hydrochlorothiazide tablets;
- a generic olmesartan/amlodipine product combined with a separate diuretic;
- formulary-preferred antihypertensive combinations from competing manufacturers.
The strongest competitive threat comes from separate generic tablets because they are usually less expensive and permit dose adjustment. A fixed-dose generic can still win among patients who value adherence and convenience, but its price generally converges toward commodity generic levels.
The commercial risk is greater in the United States than in markets where branded generics remain prevalent. U.S. pharmacy benefit managers and Medicare Part D plans typically favor low-cost generic alternatives. Retail and mail-order substitution can occur without active physician intervention when an FDA-approved therapeutically equivalent product is available.
Is there biosimilar risk for olmesartan, amlodipine and hydrochlorothiazide?
There is no biosimilar risk. The product is a small-molecule drug regulated through the generic drug pathway, not a biologic regulated under the Public Health Service Act.
The relevant competitors are ANDA applicants and manufacturers of separate generic components. The regulatory barrier is therefore lower than for biologic products, complex injectables or drug-device combinations. Manufacturing know-how may affect product quality and supply reliability, but it does not create a durable exclusivity barrier comparable to biologic cell-line or process patents.
How does Tribenzor compare with competing antihypertensive combinations?
| Product or regimen |
Commercial position |
Main advantage |
Main disadvantage |
| Tribenzor |
Mature branded or generic fixed-dose combination |
Three agents in one tablet |
Higher cost than separate generics during the branded period |
| Generic olmesartan/amlodipine |
Established generic combination |
Two-drug convenience and lower price |
Does not include a diuretic |
| Separate olmesartan, amlodipine and HCTZ |
Lowest-cost substitution route |
Flexible dose adjustment and broad availability |
Three-pill burden |
| Amlodipine/valsartan/HCTZ |
Competing triple combination |
Established alternative ARB backbone |
Different ARB and potential formulary differences |
| Losartan/HCTZ or valsartan/HCTZ |
Older generic combinations |
Low cost and broad use |
Often requires an additional agent for resistant hypertension |
Tribenzor’s clinical niche is patients who require an ARB, calcium-channel blocker and thiazide and who benefit from a single tablet. Its commercial niche is narrower because clinicians can achieve the same pharmacologic strategy with inexpensive generic products.
What is the financial trajectory of Tribenzor?
Daiichi Sankyo does not generally disclose standalone global revenue for Tribenzor. The company reports sales at broader product or regional levels, and Tribenzor has not been a separately reported growth driver comparable to major oncology products.[4]
The product’s financial trajectory follows four stages:
| Period |
Financial dynamic |
| 2010-2013 |
Launch and physician adoption, supported by triple-drug convenience |
| 2014-2016 |
Maturation of the Benicar franchise and rising pressure from generic components |
| 2017-2020 |
Generic litigation, approvals and price erosion reduced branded opportunity |
| 2021 onward |
Residual demand, generic substitution and limited revenue visibility |
Tribenzor’s revenue exposure was always smaller than the total Benicar or olmesartan franchise because it addressed a narrower segment of hypertension patients. Its economic value declined as:
- amlodipine and hydrochlorothiazide became fully commoditized;
- generic olmesartan became widely available;
- payers increased use of low-cost alternatives;
- patients and physicians adopted separate-tablet regimens;
- the brand lost the ability to command a sustained premium.
A realistic commercial model assigns the product low growth, high price erosion and declining brand contribution. Any future revenue would depend on residual branded prescribing, supply differentiation, international pricing and the presence or absence of generic fixed-dose competitors.
Which companies are challenging Tribenzor commercially?
Competition comes from two groups.
Generic manufacturers
ANDA manufacturers can compete with generic olmesartan/amlodipine/hydrochlorothiazide tablets where approved. The relevant competitive set can change rapidly because FDA approvals, commercial launches and supply arrangements are not static. Generic companies also compete indirectly through separate products containing olmesartan, amlodipine and hydrochlorothiazide.
Branded cardiovascular companies
Tribenzor competes with manufacturers selling other triple antihypertensive combinations, including products based on valsartan, losartan or other renin-angiotensin system blockers. These products compete through formulary position, physician familiarity, dosing options and contracting rather than through major therapeutic differentiation.
The market is fragmented on the manufacturing side but concentrated in payer influence. Pharmacy benefit managers, Medicare plans, hospitals and integrated health systems determine much of the net price and product access.
What manufacturing and intellectual-property barriers remain?
Manufacturing barriers are limited but not absent. A three-component tablet must meet requirements for:
- content uniformity across all active ingredients;
- dissolution performance;
- chemical and physical stability;
- control of degradation products;
- tablet segregation during production;
- validated bioequivalence;
- packaging that preserves stability.
These requirements can delay approval or create supply problems, but they do not support large long-term margins once several manufacturers qualify.
The principal remaining IP opportunity would involve a differentiated formulation, modified-release design, tablet architecture or adherence-focused delivery system. A conventional immediate-release triple tablet has limited ability to create durable protection without meaningful technical innovation.
What generic launch scenarios are most likely?
The highest-probability scenario is continued generic price erosion with progressive substitution toward separate components. A lower-probability scenario is stable demand for an authorized or branded generic that preserves convenience while selling at a modest premium to individual tablets.
A branded relaunch would face substantial obstacles:
- no new mechanism of action;
- limited payer willingness to reimburse a premium;
- strong competition from generic components;
- weak remaining patent leverage;
- low likelihood of new clinical differentiation.
The product could retain a niche among patients with adherence problems, but that niche is unlikely to support a high-growth financial profile.
Key Takeaways
- Tribenzor is the U.S. brand for olmesartan medoxomil, amlodipine besylate and hydrochlorothiazide.
- The FDA approved the product in 2010 under NDA 022582.
- The product is a mature small-molecule combination, not a biologic, so biosimilar risk does not apply.
- U.S. Patent No. 7,691,001 is the principal identified fixed-dose combination patent associated with Tribenzor.
- Generic entry risk is high because all three active ingredients are available separately.
- Separate generic tablets provide dose flexibility and usually carry lower costs than a branded fixed-dose combination.
- Daiichi Sankyo does not publicly disclose standalone Tribenzor revenue, limiting precise product-level financial modeling.
- The financial trajectory is declining or stagnant, with value concentrated in residual prescriptions, convenience and generic supply.
- Manufacturing barriers are manageable and do not create a durable competitive moat.
- The product has limited potential for renewed branded growth without a new formulation, delivery system or reimbursement advantage.
FAQs About Tribenzor Patent and Market Exposure
Is Tribenzor still commercially available?
Availability depends on country, manufacturer and the current FDA marketing-status record. Generic or authorized-generic versions may remain available even when branded supply is limited.
Can patients substitute separate olmesartan, amlodipine and hydrochlorothiazide tablets?
Yes. Clinicians can prescribe the three generic components separately, although dose equivalence and patient-specific tolerability must be assessed by the prescriber.
Does Tribenzor have pediatric exclusivity?
Any pediatric exclusivity must be confirmed in the current Orange Book and FDA regulatory record. The presence of pediatric exclusivity would affect only the applicable statutory period, not the long-term generic outlook.
Is a generic three-drug tablet automatically substitutable for Tribenzor?
Substitution depends on FDA therapeutic-equivalence determinations, the approved strength, state pharmacy law and payer policy. Separate-component substitution is clinically distinct from automatic pharmacy substitution of an equivalent fixed-dose product.
Could a new Tribenzor formulation regain market value?
A new formulation could create commercial value only if it delivers measurable adherence, tolerability, dosing or pharmacokinetic benefits and obtains enforceable intellectual-property protection. A conventional reformulation would face substantial generic and payer pressure.
References
-
U.S. Food and Drug Administration. (2010). Tribenzor prescribing information and NDA 022582. Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
-
United States Patent and Trademark Office. (2010). U.S. Patent No. 7,691,001: Pharmaceutical composition comprising olmesartan medoxomil, amlodipine and hydrochlorothiazide. https://patents.google.com/
-
Daiichi Sankyo Co., Ltd. (2024). Annual report and financial results materials. https://www.daiichisankyo.com/investors/financial-results/
